Study Title

Patients with recurrent grade 3 and grade 4 glioma will be recruited for treatment with 177Lu-PSMA.

Study Details


This interventional, clinical pilot-study will initiate and evaluate 68Ga/177Lu-PSMA theranostics in Norway as treatment alternative for patients with recurrent grade 3 and grade 4 gliomas. The main goal is to improve existing diagnostic and therapeutic methods in glioma management, and introduce a novel, well-tolerated radionuclide treatment that possibly can increase the overall survival and quality of life for a patient group that today have very short expected survival and no standard recommended therapy.


St. Olavs Hospital


Tora Solheim, MD/PhD


Live Eikenes, PhD